Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.77 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.49 |
| ▸ | TK2 | O00142 | 5/20 | 0.43 |
| ▸ | TK1 | P04183 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | DUT | P33316 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8703547 | 0.92 | KIF11 (0.71) | KIF11HRH4TK2TK1KCNH2 | |
| SCHEMBL2492363 | 0.87 | KIF11 (1.00) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL20827845 | 0.87 | KIF11 (0.63) | KIF11KCNH2SMN1; SMN2 | |
| SCHEMBL2489578 | 0.84 | KIF11 (0.56) | KIF11HRH4TK2TK1KCNH2 | |
| SCHEMBL17454867 | 0.83 | KIF11 (0.54) | KIF11HRH4TK2TK1KCNH2 | |
| SCHEMBL2493523 | 0.83 | KIF11 (0.54) | KIF11HRH4TK2TK1KCNH2 | |
| SCHEMBL11275984 | 0.82 | KIF11 (0.74) | KIF11HRH4TK2TK1DUT | |
| SCHEMBL16353449 | 0.82 | KIF11 (0.61) | KIF11TK1KCNH2SMN1; SMN2 | |
| SCHEMBL2344128 | 0.81 | KIF11 (0.60) | KIF11TK2KCNH2SMN1; SMN2 | |
| SCHEMBL2491452 | 0.81 | KIF11 (0.51) | KIF11HRH4TK2TK1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3009123-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2016-04-20 | — | — | EP | disclosed |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2015-11-19 | — | — | US | disclosed |
| CN-102264357-B | Melanin production inhibitor | POLA CHEM IND INC | 2015-04-01 | — | — | CN | disclosed |
| EP-2845587-A2 | Melanin production inhibitor | Pola Chemical Industries Inc. (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-12-11 | — | — | US | disclosed |
| US-8846012-B2 | Melanin production inhibitor | POLA CHEMICAL INDUSTRIES INC. (JP) | 2014-09-30 | — | — | US | disclosed |
| EP-2380567-A1 | MELANIN PRODUCTION INHIBITOR | Pola Chemical Industries Inc. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | POLA CHEMICAL INDUSTRIES INC. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20100256098-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2010-10-07 | — | — | US | disclosed |
| EP-2188296-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-05-26 | — | — | EP | disclosed |
| WO-2009029844-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2009-03-05 | — | — | WO | disclosed |
| EP-0509005-A1 | DIPHENYLSULPHOXIMINE MUSCARINIC RECEPTOR ANTAGONISTS | Pfizer Limited (GB) | 1992-10-21 | — | — | EP | disclosed |
| WO-1991010648-A1 | DIPHENYLSULPHOXIMINE MUSCARINIC RECEPTOR ANTAGONISTS | PFIZER LIMITED (GB) | 1991-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256098-A1 | COMPOUNDS FOR INHIBITING WIP1, PRODRUGS AND COMPOSITIONS THEREOF, AND RELATED METHODS | WAPL, WDR1, DUSP1 | KIF11 3735/4885HRH4 3415/4885TK2 2826/4885 |
| US-20110243865-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, TH | KIF11 4556/4885HRH4 231/4885TK2 2689/4885 |
| US-20150328107-A1 | MELANIN PRODUCTION INHIBITOR | TYR, MC1R, F12 | KIF11 4605/4885HRH4 118/4885TK2 2492/4885 |
| US-20140363389-A1 | MELANIN PRODUCTION INHIBITOR | TYR, F12, MC1R | KIF11 4611/4885HRH4 127/4885TK2 2433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.